What does this research mean for the field?

While immunotherapy shows preliminary potential to reduce recurrence and improve survival in hepatocellular carcinoma across disease stages, definitive long-term survival benefits have not yet been established. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize current evidence regarding the use of immune checkpoint inhibitors as neoadjuvant and adjuvant curative strategies across early, intermediate, and advanced hepatocellular carcinoma.

August 22, 2026Current OncologyOpen Access

The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

AKAnastasia KarampaUniversity of Ioannina AGAnna GoussiaHellenic Cooperative Oncology Group EBEvangelos G. BaltagiannisUniversity of Ioannina

Discussion

Member takes

Overview

Review reveals potential of perioperative immune checkpoint inhibitors in hepatocellular carcinoma, indicating ongoing trials are essential to confirm long-term survival benefits.

Key Points

To synthesize current evidence regarding the use of immune checkpoint inhibitors as neoadjuvant and adjuvant curative strategies across early, intermediate, and advanced hepatocellular carcinoma.
Reviewed completed and ongoing clinical trials evaluating immune checkpoint inhibitors as monotherapy, combined with anti-angiogenic agents, or as dual-checkpoint blockade.
Assessed perioperative approaches and long-term outcomes from trials including IMbrave050 following radical liver resection or ablation.
Adjuvant immunotherapy with atezolizumab and bevacizumab demonstrated initial improvements in recurrence-free survival for high-risk patients in preliminary IMbrave050 trial findings.
Recurrence-free survival benefits were not sustained at median follow-up, and clear overall survival advantages across disease stages remain unestablished pending mature trial data.
Integrating checkpoint inhibitors into pre- and post-operative regimens shows promise for improving resectability and reducing post-surgical recurrence rates exceeding 70%.

Cite This Study

Karampa et al. (2026) studied this question.

synapsesocial.com/papers/6a895fd3ca7ade938187eba5 https://doi.org/10.3390/curroncol33080492

View Full Paper

Ask AI

Bookmark

August 22, 2026Current OncologyOpen Access

The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

AKAnastasia KarampaUniversity of Ioannina AGAnna GoussiaHellenic Cooperative Oncology Group EBEvangelos G. BaltagiannisUniversity of Ioannina

Discussion

Member takes

Overview

Review reveals potential of perioperative immune checkpoint inhibitors in hepatocellular carcinoma, indicating ongoing trials are essential to confirm long-term survival benefits.

Key Points

To synthesize current evidence regarding the use of immune checkpoint inhibitors as neoadjuvant and adjuvant curative strategies across early, intermediate, and advanced hepatocellular carcinoma.
Reviewed completed and ongoing clinical trials evaluating immune checkpoint inhibitors as monotherapy, combined with anti-angiogenic agents, or as dual-checkpoint blockade.
Assessed perioperative approaches and long-term outcomes from trials including IMbrave050 following radical liver resection or ablation.
Adjuvant immunotherapy with atezolizumab and bevacizumab demonstrated initial improvements in recurrence-free survival for high-risk patients in preliminary IMbrave050 trial findings.
Recurrence-free survival benefits were not sustained at median follow-up, and clear overall survival advantages across disease stages remain unestablished pending mature trial data.
Integrating checkpoint inhibitors into pre- and post-operative regimens shows promise for improving resectability and reducing post-surgical recurrence rates exceeding 70%.

Cite This Study

Karampa et al. (2026) studied this question.

synapsesocial.com/papers/6a895fd3ca7ade938187eba5 https://doi.org/10.3390/curroncol33080492

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark